Xia Y - Search Results

1

Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.

Zhao J, Guo Y, Feng T, Rong D, Kong X, Huang T, Lopez-Lopez V, Yarmohammadi H, Sakamoto Y, Zhu D, Yao A, Xia Y. Zhao J, et al. Among authors: xia y. J Gastrointest Oncol. 2023 Dec 31;14(6):2549-2558. doi: 10.21037/jgo-23-590. Epub 2023 Dec 27. J Gastrointest Oncol. 2023. PMID: 38196523 Free PMC article.

2

Lithium exacerbates hepatic ischemia/reperfusion injury by inhibiting GSK-3β/NF-κB-mediated protective signaling in mice.

Xia Y, Rao J, Yao A, Zhang F, Li G, Wang X, Lu L. Xia Y, et al. Eur J Pharmacol. 2012 Dec 15;697(1-3):117-25. doi: 10.1016/j.ejphar.2012.09.009. Epub 2012 Oct 7. Eur J Pharmacol. 2012. PMID: 23051669

3

m6A modification of circHPS5 and hepatocellular carcinoma progression through HMGA2 expression.

Rong D, Wu F, Lu C, Sun G, Shi X, Chen X, Dai Y, Zhong W, Hao X, Zhou J, Xia Y, Tang W, Wang X. Rong D, et al. Among authors: xia y. Mol Ther Nucleic Acids. 2021 Sep 14;26:637-648. doi: 10.1016/j.omtn.2021.09.001. eCollection 2021 Dec 3. Mol Ther Nucleic Acids. 2021. PMID: 34703649 Free PMC article.

4

Regulatory T Cells Improved the Anti-cirrhosis Activity of Human Amniotic Mesenchymal Stem Cell in the Liver by Regulating the TGF-β-Indoleamine 2,3-Dioxygenase Signaling.

Deng Z, Zhou J, Mu X, Gu J, Li X, Shao Q, Li J, Yang C, Han G, Zhao J, Xia Y. Deng Z, et al. Among authors: xia y. Front Cell Dev Biol. 2021 Oct 12;9:737825. doi: 10.3389/fcell.2021.737825. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34712665 Free PMC article.

5

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.

Xia Y, Tang W, Qian X, Li X, Cheng F, Wang K, Zhang F, Zhang C, Li D, Song J, Zhang H, Zhao J, Yao A, Wu X, Wu C, Ji G, Liu X, Zhu F, Qin L, Xiao X, Deng Z, Kong X, Li S, Yu Y, Xi W, Deng W, Qi C, Liu H, Pu L, Wang P, Wang X. Xia Y, et al. J Immunother Cancer. 2022 Apr;10(4):e004656. doi: 10.1136/jitc-2022-004656. J Immunother Cancer. 2022. PMID: 35379737 Free PMC article. Clinical Trial.

6

Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study.

Chen X, Li W, Wu X, Zhao F, Wang D, Wu H, Gu Y, Li X, Qian X, Hu J, Li C, Xia Y, Rao J, Dai X, Shao Q, Tang J, Li X, Shu Y. Chen X, et al. Among authors: xia y. Front Oncol. 2022 May 31;12:909035. doi: 10.3389/fonc.2022.909035. eCollection 2022. Front Oncol. 2022. PMID: 35712486 Free PMC article.

7

Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma.

Kong X, Zheng Z, Song G, Zhang Z, Liu H, Kang J, Sun G, Sun G, Huang T, Li X, Rong D, Wang K, Tang W, Xia Y. Kong X, et al. Among authors: xia y. Front Immunol. 2022 Jun 22;13:876048. doi: 10.3389/fimmu.2022.876048. eCollection 2022. Front Immunol. 2022. PMID: 35812439 Free PMC article.

8

Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.

Cao H, Huang T, Dai M, Kong X, Liu H, Zheng Z, Sun G, Sun G, Rong D, Jin Z, Tang W, Xia Y. Cao H, et al. Among authors: xia y. Int J Biol Sci. 2022 Aug 21;18(14):5369-5390. doi: 10.7150/ijbs.73949. eCollection 2022. Int J Biol Sci. 2022. PMID: 36147461 Free PMC article. Review.

9

Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study.

Zhao J, Guo Y, Ding W, Han G, Jiang C, Yang C, Hu Y, Zhang L, Wu C, Ni M, Kong X, Huang T, Zhang C, Xia Y. Zhao J, et al. Among authors: xia y. Front Oncol. 2022 Oct 6;12:965711. doi: 10.3389/fonc.2022.965711. eCollection 2022. Front Oncol. 2022. PMID: 36276134 Free PMC article.

10

Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy.

Sun G, Liu H, Zhao J, Zhang J, Huang T, Sun G, Zhao S, Zhang Z, Cao H, Rong D, Kong X, Ji Q, Liu L, Wang X, Tang W, Xia Y. Sun G, et al. Among authors: xia y. J Immunother Cancer. 2022 Dec;10(12):e005655. doi: 10.1136/jitc-2022-005655. J Immunother Cancer. 2022. PMID: 36600662 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16,244 results

Search Page

Filters